Jeff Hartlin is a partner and chair of the Corporate practice of Paul Hastings in Palo Alto and is based in the firm's Palo Alto and San Diego offices. Mr. Hartlin concentrates his practice in corporate law, capital-raising, mergers & acquisitions and securities and has represented public and private companies in the software, hardware, information technology, biotechnology/biopharmaceutical, medical device, semiconductor, clean technology and financial industries. His experience in all aspects of the capital raising process includes representing issuers, underwriters, venture capital firms and placement agents in IPOs, SPAC financings, registered directs, at-the-market offerings and rights offerings, as well as venture and angel-backed private placements, PIPEs, debt financings, Rule 144A transactions, reverse mergers and Regulation S offerings. Mr. Hartlin also routinely represents startup and other early-stage companies from incorporation through early financing, pre-IPO capital raising, IPO and eventual sale. Mr. Hartlin has represented several public and private companies in equity and debt private placements with a combined value of several billion. He also represents Nasdaq and NYSE companies with their periodic reporting requirements and listing qualification issues. He regularly advises boards of directors and management of public and private companies regarding corporate governance issues, including the Sarbanes-Oxley Act, the Dodd-Frank Act and the JOBS Act. Mr. Hartlin also represents public and private corporations in merger and acquisition transactions, de-SPAC transactions, joint ventures, leveraged and non-leveraged acquisitions, spinoffs, spin-ins and dispositions. He is frequently engaged to advise companies in activist stockholder matters.
Accolades and Recognitions
Mr. Hartlin was selected for inclusion in multiple editions of San Diego Super Lawyers
Mr. Hartlin was selected for inclusion in multiple editions of Southern California Super Lawyers
Mr. Hartlin was named a winner of the M&A Advisor 2012 (West) '40 Under 40' Award, which recognizes the emerging leaders of the M&A, financing, and turnaround industries
Chambers USA named Mr. Hartlin to multiple of its lists of leading lawyers in California capital markets transactions
University of Virginia School of Law, J.D. (Editor-in-Chief of the Virginia Tax Review )
University of California Davis, B.A. (Phi Beta Kappa); NCAA Men's Varsity Soccer and Track & Field
Mentioned in The Daily Journal and Law360 regarding Viking Therapeutics, Inc.'s initial public offering
Mentioned in The Recorder, The Daily Journal and Law360 regarding representing Kosei, Inc. its its sale to Pinterest, Inc.
RR Donnelley presents to SEC Hot Topics Institute, San Diego, CA
Alliance Advisors, Society of Corporate Secretaries & Governance Professionals and Paul Hastings LLPpresent ISS Proxy Voting Guidelines, Chicago, IL
Society of Corporate Secretaries and Governance Professionals Presents Hot Issues in Private Company Governance, Colorado Springs, CO
RR Donnelley presents the SEC Hot Topics Institute, San Diego, CA
Paul Hastings, Citadel Securities, PricewaterhouseCoopers, MacKenzie Partners and RR Donnelley Present a Briefing on Proxy Access, Executive Compensation and Corporate Governance under the Dodd-Frank (Wall Street Reform) Act:
Paul Hastings, Houlihan Lokey, BDO Seidman and Thomas Weisel Partners Present a Briefing on Registered Direct and At-the-Market Equity Offerings: Trends for Raising Capital in 2010, Los Angeles, CA
RR Donnelley presents the SEC Hot Topics Institute, San Diego, CA
Stafford Publications presents: A Roadmap to Emerging Financing Alternatives Leveraging Opportunities in Rights Offerings, Registered Directs, and More
Houlihan Lokey, Paul Hastings and Sagient/PlacementTracker Present an Interactive Webinar: PIPEs: The Ever-Evolving Financing Technique
Member of the Board of Directors of the National Kidney Foundation of Northern California
Member of the California State Bar Association
Member of the Committee on Federal Regulation of Securities of the American Bar Association
Hero Research, Inc. in its sale to People.ai
Jasper Therapeutics, Inc. in its reverse merger (deSPAC) with Amplitude Healthcare Acquisition Corporation
Seqster PDM in its preferred stock financing
River Financial in its preferred stock financing
Masimo Corporation in its acquisition of LiDCO Group Plc
Paige.ai, Inc. in its preferred stock financing
Orphion Therapeutics, Inc. in its preferred stock financing
Mohawk Group Holdings in its acquisitions of Truweo and various e-commerce business brands
Valente Sherman, Inc. (VISO Trust) in its preferred stock financing
Zycada Networks, Inc. in its preferred stock financing
Sorrento Therapeutics, Inc. in its acquisition of SmartPharm Therapeutics, Inc.
Indapta Therapeutics, Inc. in its financing transactions
Kasha Global Inc. in its preferred stock financing
Jasper Therapeutics, Inc. in its preferred stock financing
kimkim, Inc. in its financing transaction
DerivaDEX in its financing transaction
Masimo Corporation in its acquisition of the Connected Care Business from NantHealth, Inc.
Polychain Capital in its investments
CareDx, Inc. in its acquisitions of TransChart, XynManagement, Inc. and OTTR
Veriflow Systems, Inc. in its sale to VMware, Inc.
PredictImmune Ltd. in its preferred stock financing
Mohawk Group Holdings in its initial public offering and additional financings
Scilex Holding Company in its acquisition of Semnur Pharmaceuticals, Inc.
selectION, Inc. in its preferred stock financing
Aardvark Therapeutics, Inc. in its preferred stock financing
Neubase Therapeutics, Inc. in its reverse merger with Ohr Pharmaceutical, Inc. and financing transactions
OneStream Software LLC in its financing by KKR
Zededa, Inc. in its preferred stock financings
Oasis Labs in its financings and corporate matters
Scilex Pharmaceuticals Inc. in its debt financing structured by Morgan Stanley
Integrated DNA Technologies in its sale to Danaher
Seelos Therapeutics, Inc. in its reverse merger with Apricus Biosciences, Inc. and financings
BlastWave,Inc. in its preferred stock financing
Hummingbird Regtech, Inc. in its preferred stock financings
healthblock, Inc. in its financing led by XSeed Capital
Integrated DNA Technologies, Inc. in its sale to Danaher Corporation
Shift Financial, Inc. in its merger with Ledge, Inc.
Mobile Gaming Technologies in its partnership with Arsenal Football Club
Redmile Group, LLC in its preferred stock financing of Alder BioPharmaceuticals, Inc.
Sorrento Therapeutics, Inc. and TNK Therapeutics, Inc. in their joint venture with Celularity, Inc.
Corsair Components in its sale to EagleTree Capital
Darmiyan, Inc. in its financing transactions
Mission Bio, Inc. in its venture-backed financing transactions
Integrated DNA Technologies, Inc. in its partnership with Illumina
TNK Therapeutics, Inc. in its acquisition of Virttu Biologics
Sorrento Therapeutics, Inc. in its underwritten public offerings
Tapclicks, Inc. in its debt financing by SaaS Capital
J.T. Posey Company in its sale to RoundTable Healthcare Partners
Biopop in its sale to Intrexon Corporation
Enplas America, Inc. in its equity and debt investments
Matrix Industries, Inc. in its equity and debt financing transactions
Eprazel, Inc. in its strategic financing by Renren, Inc.
Sorrento Therapeutics, Inc. in its acquisition of Scilex Pharmaceuticals Inc.
Seelos Therapeutics, Inc. in its licensing transaction with Ligand Pharmaceuticals Incorporated
CareDx, Inc. in its underwritten public offerings and its stock option exchange program
GenapSys, Inc. in its preferred stock and debt financing transactions
Veriflow Systems, Inc. in its financing by Menlo Ventures and New Enterprise Associates (NEA)
Samumed, LLC in its financing transactions
SMA Solar Technology AG in its investment in Tigo Energy, Inc.
Filld, Inc. in its financings by Lightspeed Partners, Javelin Partners and PivotNorth
Plum, Inc. in its strategic financing by Renren, Inc.
Procera Networks, Inc. in its sale to Francisco Partners
Viking Therapeutics, Inc. in its initial public offering, follow-on public offerings and equity line financing
Kosei, Inc. in its sale to Pinterest, Inc.
Boomtown Networks, Inc. in its strategic financings
Sorrento Therapeutics, Inc. in its joint venture with NantWorks and financing transactions
RightSignature LLC in its sale to Citrix Systems
Integrated DNA Technologies, Inc. in the strategic financing by Summit Partners
Samsung Electronics Co., Ltd. in the sale of its joint venture stake to, and strategic investment in, Corning Incorporated
Fox Factory in its initial public offering
YFind Technologies Private Limited in its sale to Ruckus Wireless, Inc.
Corsair Components, Inc. in the strategic financing by Francisco Partners and its acquisition of Simple Audio Limited
Procera Networks, Inc. in its acquisition of Vineyard Networks Inc.
The underwriters, led by Goldman, Sachs & Co. and Deutsche Bank Securities, in the initial public offering of Envivio, Inc.
Monitise plc in its acquisition of ClairMail, Inc.
Samsung Electronics Co., Ltd. in the sale of its hard disk-drive unit to Seagate Technology
Masimo Corporation in its acquisitions of Phasein AB and Spire Semiconductor, LLC
Exceptional Cloud Services in its sale to Rackspace Hosting, Inc.
Samsung Electronics, Co., Ltd. in its acquisition of Nexus Dx
Houlihan Lokey as exclusive dealer-manager for Network Communications, Inc.'s senior notes exchange offer, consent solicitation and balance sheet restructuring
Hanwha Chemical in its strategic investment in Solarfun Power Holdings
Mint Software, Inc. (mint.com) in its sale to Intuit, Inc.
Sybase, Inc. in its 144A-for-life convertible notes offering
AviaraDx, Inc. in its sale to bioMerieux
Masimo Corporation in its initial public offering
Warburg Pincus in its exchangeable bond investment in Synutra International, Inc.
CryoCor, Inc. in its initial public offering
The Titan Corporation in its acquisition of Jaycor, Inc. in a stock-for-stock merger
Favrille, Inc. in its initial public offering
MannKind Corporation in its initial public offering
Applied Micro Circuits Corporation in its acquisition of JNI Corporation
Woodside Biomedical, Inc. in its sale to Abbott Laboratories